Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Disruption of exon recognition and misregulation of alternative splicing are a common cause of human diseases including
cancer progression. Currently the analysis of cancer-specific alternative splicing is a promising step forward in basic and
translational molecular biology.Traditional medicine has a long history and is still the major source of medicine in developing
countries. Approximately 70% of the South African population consults traditional healers, perpetuating the need for scientific
appraisal of traditional medicine as a means to establish its efficiency and safety. Also, pharmacological and phytochemical
insights into several plants have led to the discovery of novel chemicals and therefore novel drugs. Alternatively, such novel
chemical structures can serve as lead compounds/templates for the design of new drugs. The aim was to ascertain if the
South African medicinal plants have anticancer splicing activity. 10c cells were treated with
Tulbhaghiaviolacea
and
Cotyledon
orbiculata
, followed by mRNA extraction and RT-PCR. The results showed that
Tulbhaghiaviolacea
and
Cotyledon orbiculata
extracts have anti-cancer splicing activity on the BCLX and the AXL apoptosis genes. Additionally
Cotyledon orbiculata
extract
has an anticancer splicing activity of the angiogenesis gene VEGF165. VEGF Elisa also confirmed the VEGF165 VEGF165b
splicing switch. It was shown that South African medicinal plants have anti-cancer splicing activity. It is being continued to
screen more medicinal plants and will select those extracts with anti-cancer splicing activity for further studies. These further
studies should identify numerous splicing pathways and completely elucidate the splicing target compounds that may serve as
novel anti-cancer drugs or lead compounds.
Biography
Zodwa Dlamini is the Deputy Executive Dean at the University of South Africa. She is the Vice Chairperson of the South African Medical Research Council
Board. She also represents the National Department of Health in the Department of Science and Technology Scientific Advisory Committee on Preclinical Drug
Development Platform. She holds an appointment as an honorary research fellow at the University of Bristol, UK. She is a Professor of Functional Genomics and
Molecular Genetics. Her research interests include characterization of genes involved in cancer and apoptosis with a focus on a Ubiquitin-like DWNN and proteins
involved in ceramide signaling.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals